Ani Pharmaceuticals (ANIP) Change in Account Payables (2012 - 2026)

Ani Pharmaceuticals has disclosed Change in Account Payables across 15 years of filings, most recently posting -$1.1 million for Q2 2026.

• In Q2 2026, Change in Account Payables fell 136.28% year-over-year to -$1.1 million; the TTM figure through Jun 2026 stood at $10.8 million (up 944.94% YoY), while the FY2025 annual figure was $15.2 million, up 3064.09% from the prior year.
• Change in Account Payables came in at -$1.1 million for Q2 2026 at Ani Pharmaceuticals, down from $5.4 million in the prior quarter.
• In the past five years, Change in Account Payables ranged from a high of $13.8 million in Q3 2025 to a low of -$9.1 million in Q3 2022.
• Average Change in Account Payables over 5 years is $1.8 million, with a median of $2.9 million recorded in 2023.
• The largest YoY upside for Change in Account Payables was 753.23% in 2022 against a maximum downside of 602.32% in 2022.
• Over 5 years, Change in Account Payables stood at $10.1 million in 2022, then sank by 72.38% to $2.8 million in 2023, then tumbled by 345.36% to -$6.8 million in 2024, then dropped by 6.07% to -$7.2 million in 2025, then surged by 84.57% to -$1.1 million in 2026.
• Per Business Quant data, the three most recent Change in Account Payables figures were -$1.1 million in Q2 2026, $5.4 million in Q1 2026, and -$7.2 million in Q4 2025.